In many ways, the year in diagnostics can be characterized as “more of the same.” The biggest newsmaker was FDA’s finally taking steps toward establishing an oversight framework for the regulation of laboratory-developed tests.

Genzyme made a significant investment in RNA interference in a new deal with Alnylam; J&J sold Ortho-Clinical Diagnostics to Carlyle Group for just over $4 billion; biopharma financing reached $2.8 billion in January, more than doubling December’s total; and device companies only raised money privately only in January, mostly from late-stage venture rounds.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January through February 2014.